Intra-cerebral ventricular infusion of 5-iodo-2-deoxyuridine (IUDR) as a radiosensitizer in the treatment of a rat glioma.
The efficacy of 5-iodo-2-deoxyuridine (IUDR) as a radiosensitizer when administered by continuous infusion into the cerebral spinal fluid (CSF) of the lateral cerebral ventricle was evaluated in a 9L gliosarcoma rat brain tumor model. Stereotactic implantation of a 5 x 10(4) tumor cell suspension into the left caudate nucleus was carried out in four groups of 10 rats each. Control animals had a median survival of 16.9 days (range 16-21 days). IUDR, 8.4 mg over 7 days administered by continuous infusion into the left lateral ventricle produced a slight survival advantage (median survival 21.5 days, range 12-56). Irradiation of the entire brain, 8 Gy on days 4, 6 and 7 after tumor cell implantation also produced a slight improvement in survival (median 19.5 days, range 17-34). The combination of radiation and IUDR infusion into the CSF produced a marked survival advantage (median 30.5, range 22-54) compared to the control and single modality treatment groups. This is the first demonstration of the effectiveness of IUDR as a radiosensitizer when administered into the lateral cerebral ventricle in the treatment of an intraparenchymal brain tumor.
Deutsch
M
M
Department of Radiation Oncology, University of Pittsburgh School of Medicine, PA.
Rewers
A B
AB
Redgate
S
S
Fisher
E R
ER
Boggs
S S
SS
D000818:Animals; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D003643:Death; D005910:Glioma / Q000188:drug therapy* / Q000532:radiotherapy; D007065:Idoxuridine / Q000008:administration & dosage* / Q000627:therapeutic use; D007276:Injections, Intraventricular; D008297:Male; D009368:Neoplasm Transplantation; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D051381:Rats; D011916:Rats, Inbred F344
D011838:Radiation-Sensitizing Agents; D007065:Idoxuridine